EyePoint Pharmaceuticals News Releases http://investors.psivida.com/ EyePoint Pharmaceuticals News Releases en EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-reports-inducement-grants-under-0 WATERTOWN, Mass. , June 13, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported the grant of inducement awards to Scott Jones , EyePoint’s newly Thu, 13 Jun 2019 07:00:00 -0400 EyePoint Pharmaceuticals News Releases 14056 EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-strengthens-executive-leadership-team - Scott Jones Appointed as Chief Commercial Officer - - Said Saim, Ph.D., Appointed as Chief Technology Officer - WATERTOWN, Mass. , June 10, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing Mon, 10 Jun 2019 07:00:00 -0400 EyePoint Pharmaceuticals News Releases 14041 EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-present-upcoming-investor-conferences-1 WATERTOWN, Mass. , May 15, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled Wed, 15 May 2019 07:00:00 -0400 EyePoint Pharmaceuticals News Releases 14011 EyePoint Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Company Progress http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-reports-first-quarter-2019-financial - YUTIQ™ and DEXYCU™ commercially launched in 1Q2019 – - YUTIQ recommended for specific J-code by Centers for Medicare & Medicaid Services - - Debt refinancing and equity public offering generated net proceeds of approximately $30.0 million - - Company optimistic that current cash balance and cash Wed, 08 May 2019 06:00:00 -0400 EyePoint Pharmaceuticals News Releases 13981 EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-presents-positive-yutiqtm-36-month   –  36-month data showed a uveitis eye flare recurrence rate of 56.3% in YUTIQ-treated eyes vs. 92.9% in sham eyes -              – Durability of 36-month data and safety support long-term efficacy of YUTIQ - WATERTOWN, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. Wed, 01 May 2019 07:00:00 -0400 EyePoint Pharmaceuticals News Releases 13976 EyePoint Pharmaceuticals Announces First Quarter 2019 Financial Results Release Date and Conference Call Information http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-first-quarter-2019-financial WATERTOWN, Mass. , April 23, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its first quarter ended March 31, 2019 on Wednesday, May 8 . Tue, 23 Apr 2019 07:00:00 -0400 EyePoint Pharmaceuticals News Releases 13956 EyePoint Pharmaceuticals to Present at Upcoming Medical Conferences http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-present-upcoming-medical-conferences Two Presentations Highlighting YUTIQ™ to be Presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Data from Two Phase 3 Studies of DEXYCU ™ to be presented at the 2019 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Tue, 16 Apr 2019 07:00:00 -0400 EyePoint Pharmaceuticals News Releases 13941 EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-present-upcoming-investor-conferences-0 WATERTOWN, Mass. , April 02, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that members of the management team are scheduled to present at the Tue, 02 Apr 2019 07:00:00 -0400 EyePoint Pharmaceuticals News Releases 13926 EyePoint Pharmaceuticals Announces Pricing of Public Offering of Common Stock http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-pricing-public-offering WATERTOWN, Mass. , March 28, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the pricing of an underwritten public offering of 10,526,500 shares Thu, 28 Mar 2019 09:11:00 -0400 EyePoint Pharmaceuticals News Releases 13886 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock http://investors.psivida.com/news-releases/news-release-details/eyepoint-pharmaceuticals-announces-proposed-public-offering WATERTOWN, Mass. , March 27, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it intends to offer and sell shares of its common stock in an Wed, 27 Mar 2019 16:05:00 -0400 EyePoint Pharmaceuticals News Releases 13876